Autism Disorder Increase – Human Fetal DNA
A study published in the September issue of the Journal of Public Health and Epidemiology is perhaps the first to examine the relationship between vaccines manufactured from human fetal cell lines and autism.
In this study, Theresa Deisher and colleagues from the Sound Choice Pharmaceutical Institute (SCPI) Seattle, WA, USA identify a correlation between the increase in autism disorder (AD) when fetal and retroviral contaminants are found in childhood vaccines.
The authors of this study found that the birth year change points (sudden spike in cases) of children with AD corresponded to the introduction of vaccines manufactured using human fetal cell lines, containing fetal and retroviral contaminants. This pattern was repeated in the US, UK, Western Australia and Denmark.
Of note, previous studies have shown that vaccines that have been manufactured using the WI-38 fetal cell line are contaminated with fragments of the human endogenous retrovirus HERV-K . Previous research also indicates that human fetal DNA fragments may play a role in the induction autoimmune reactions, while both DNA fragments and retroviruses are known to potentiate genomic insertions and mutations.
Thus, the authors suggest that retroviral and human DNA fragment contaminants in childhood vaccines may trigger or play a major role in the development of AD. They also point that these contaminants were not present prior to the first US autistic disorder change point.
According to the authors this overlooked potential trigger for the worldwide AD epidemic demands additional studies related to the safety of childhood vaccines, particularly since reverting to animal based manufacturing methods is readily available.
Selected from BrainImmune on Scoop.it.
Source: Journal of Public Health and Epidemiology, Vol. 6(9), pp. 271-284, September 2014, DOI: 10.5897/JPHE2014.0649
Cover Image: Dr. Theresa Deisher, a PhD in Molecular and Cellular Physiology from Stanford University, Founder of AVM Biotechnology and Sound Choice Pharmaceutical Institute.